Ajanta Pharma Limited has complied with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, by publishing its un-audited financial results for the quarter and nine months ended December 31, 2025. The results were published on January 31, 2026, in the Mumbai editions of the Business Standard and Navakal newspapers. The unaudited standalone financial results for the quarter ended December 31, 2025, show total income from operations at ₹1,472.67 lakh, with a profit after tax of ₹18.79 lakh. For the nine months ended December 31, 2025, the total income from operations was ₹6,391.76 lakh, and the profit after tax was ₹45.95 lakh. Basic Earnings Per Share (EPS) for the quarter stood at ₹0.21, and diluted EPS was also ₹0.21. For the nine-month period, basic and diluted EPS were ₹0.50.
